Compare ACNB & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACNB | QTTB |
|---|---|---|
| Founded | 1857 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.6M | 25.1M |
| IPO Year | N/A | N/A |
| Metric | ACNB | QTTB |
|---|---|---|
| Price | $50.69 | $3.06 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $49.50 | $7.33 |
| AVG Volume (30 Days) | 28.6K | ★ 9.0M |
| Earning Date | 01-22-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.34 | N/A |
| Revenue | ★ $136,676,000.00 | N/A |
| Revenue This Year | $41.47 | N/A |
| Revenue Next Year | $3.31 | N/A |
| P/E Ratio | $15.43 | ★ N/A |
| Revenue Growth | ★ 28.45 | N/A |
| 52 Week Low | $35.70 | $1.35 |
| 52 Week High | $53.41 | $6.37 |
| Indicator | ACNB | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 54.77 | 53.04 |
| Support Level | $48.50 | $2.83 |
| Resistance Level | $53.41 | $3.96 |
| Average True Range (ATR) | 1.16 | 0.35 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 40.92 | 25.00 |
ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.